Evidence map›Paper›PMID 30513922›Full record

ReviewNutrients2018

Health Effects of Resveratrol: Results from Human Intervention Trials.

Sonia L Ramírez-Garza, Emily P Laveriano-Santos, María Marhuenda-Muñoz, Carolina E Storniolo, Anna Tresserra-Rimbau, Anna Vallverdú-Queralt, Rosa M Lamuela-Raventós

Open access · goldAbstract readReview
In one paragraph

Review in Nutrients, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 133 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
133citing papers in PubMed, 4 pooled it
16.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

133 citing papers in PubMed, 4 syntheses or guidelines pooled it, 235 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Review
  11. Review
  12. Article
  13. Article
  14. Review
  15. Evaluation of Molecular Responses and Longevity Markers inInternational journal of molecular sciences · 2026
    Article
  16. Resveratrol as a Regulator of Inflammation, Oxidative Stress, and Glucose Stability in Diabetes.Anti-inflammatory & anti-allergy agents in medicinal chemistry · 2026
    Review
  17. Review
  18. Review
  19. Article
  20. Review

73 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Sonia L Ramírez-GarzaDepartment of Nutrition, Food Science and Gastronomy, School of Pharmacy and Food Sciences XaRTA, Institute of Nutrition and Food Safety (INSA-UB), University of Barcelona, 08921 Santa Coloma de Gramenet, Spain. sonialrmz@gmail.com.
Emily P Laveriano-SantosDepartment of Nutrition, Food Science and Gastronomy, School of Pharmacy and Food Sciences XaRTA, Institute of Nutrition and Food Safety (INSA-UB), University of Barcelona, 08921 Santa Coloma de Gramenet, Spain. elaversa21@alumnes.ub.edu.ORCID 0000-0002-4852-6074
María Marhuenda-MuñozDepartment of Nutrition, Food Science and Gastronomy, School of Pharmacy and Food Sciences XaRTA, Institute of Nutrition and Food Safety (INSA-UB), University of Barcelona, 08921 Santa Coloma de Gramenet, Spain. mmarhuendam@ub.edu.
Carolina E StornioloDepartment of Nutrition, Food Science and Gastronomy, School of Pharmacy and Food Sciences XaRTA, Institute of Nutrition and Food Safety (INSA-UB), University of Barcelona, 08921 Santa Coloma de Gramenet, Spain. carolina.e.storniolo@gmail.com.
Anna Tresserra-RimbauHuman Nutrition Unit, University Hospital of Sant Joan de Reus, Department of Biochemistry and Biotechnology, Faculty of Medicine and Health Sciences, Pere Virgili Health Research Center, University Rovira i Virgili, 43201 Reus, Tarragona, Spain. anna.tresserra@iispv.cat.ORCID 0000-0002-7022-9041
Anna Vallverdú-QueraltDepartment of Nutrition, Food Science and Gastronomy, School of Pharmacy and Food Sciences XaRTA, Institute of Nutrition and Food Safety (INSA-UB), University of Barcelona, 08921 Santa Coloma de Gramenet, Spain. avallverdu@ub.edu.ORCID 0000-0001-6287-799X
Rosa M Lamuela-RaventósDepartment of Nutrition, Food Science and Gastronomy, School of Pharmacy and Food Sciences XaRTA, Institute of Nutrition and Food Safety (INSA-UB), University of Barcelona, 08921 Santa Coloma de Gramenet, Spain. lamuela@ub.edu.ORCID 0000-0002-1287-4560
Instituto de Salud Carlos III · ESInstitut de Recerca Biomèdica Catalunya Sud · ESUniversitat de Barcelona · ES

Funding

HISTORICAL PROSPECTIVE--ORGANOCHLORINES/BREAST CANCERR03CA075329 · NCI · COLORADO STATE UNIVERSITY-FORT COLLINS · PI KEEFE, THOMAS J · 1997 to 1998
–
Generalitat de Catalunya 2017 SGR 196Instituto de Salud Carlos III CIBEROBN CB12/03/30020Ministerio de Ciencia, Innovación y Universidades AGL2016-75329-R
6 · The paper itself

Abstract

The effect of resveratrol (RV) intake has been reviewed in several studies performed in humans with different health status. The purpose of this review is to summarize the results of clinical trials of the last decade, in which RV was determined in biological samples such as human plasma, urine, and feces. The topics covered include RV bioavailability, pharmacokinetics, effects on cardiovascular diseases, cognitive diseases, cancer, type 2 diabetes (T2D), oxidative stress, and inflammation states. The overview of the recent research reveals a clear tendency to identify RV in plasma, showing that its supplementation is safe. Furthermore, RV bioavailability depends on several factors such as dose, associated food matrix, or time of ingestion. Notably, enterohepatic recirculation of RV has been observed, and RV is largely excreted in the urine within the first four hours after consumption. Much of the research on RV in the last 10 years has focused on its effects on pathologies related to oxidative stress, inflammatory biomarkers, T2D, cardiovascular diseases, and neurological diseases.

Indexed as

Biological AvailabilityCardiovascular DiseasesCognitive DysfunctionDiabetes Mellitus, Type 2HumansResveratrolResveratrolantioxidantbioavailabilitymetabolic diseasesobesity

Identifiers

PMID30513922
PMCPMC6317057
OpenAlexW2902539416

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.